PDE9A抑制剂:策略性市场洞察和开发平台(管线)的展望-2025年

PDE9A 抑制剂领域正处于转折点，市场不断增长，未满足的需求巨大，临床证据有力。拥有一流选择性、临床差异化和策略合作伙伴关係的公司预计将在心血管和认知治疗领域抓住数十亿美元的机会。

磷酸二酯酶 9A (PDE9A) 已成为药物开发的宝贵靶点，特别是由于其在心血管和神经退化性疾病中的作用。透过调节环核苷酸水平，PDE9A 抑制剂提供了一种新的作用机制，可能为心臟衰竭（HFpEF、HFrEF）、阿兹海默症和精神分裂症带来突破性的治疗。然而，儘管PDE9A抑制剂前景光明，但它尚未获得临床批准，这给药物开发商和投资者带来了高风险、高回报的机会。

PDE9A 在细胞内讯号传导中起着关键作用，调节 cGMP 和 cAMP 的水平。透过阻断 PDE9A 的活性，抑制剂可以阻止这些重要讯号分子的降解，从而增强血管舒张、神经保护和代谢调节。透过这些机制，PDE9A 抑制剂可能代表心血管和神经系统治疗范式中的突破性疗法，特别是在涉及 cGMP 失调的病理学中。

PDE9A 抑制剂市场非常活跃，各大公司正在开发许多活性候选药物，其中包括：Cardurion Pharmaceuticals 凭藉两项正在开发的资产引领市场。 Ignota Labs 已筹集 690 万美元的种子资金，专注于人工智慧驱动的药物研发。卫材和勃林格殷格翰正在开发用于治疗心臟衰竭和神经系统疾病的 PDE9A 抑制剂。

儘管有这样的势头，但选择性的课题依然存在。具体来说，它将 PDE9A 与 PDE1 等其他磷酸二酯酶区分开来，后者在受到抑制时可能会引起与中枢神经系统相关的副作用。

广谱 PDE 抑制剂市场规模预计将从 2024 年的 40.6 亿美元成长到 2032 年的 69.2 亿美元，复合年增长率为 6.88%。

由于 PDE9A 抑制剂尚未获得批准，早期投资可能提供先发优势，特别是在合作、收购和授权交易方面。

本报告提供全球PDE9A抑制剂市场相关调查，提供市场现状，以及收购，授权及联盟契约，竞争情形，市场机会等资讯。

目录

第1章 报告书概要

第2章 概要

• PDE9A抑制剂的介绍与作用
• PDE9A 抑制剂的潜在问题
• PDE9A 抑制剂：心血管领域极具前景的标靶
• PDE9A抑制剂的临床应用

第3章 PDE9A抑制剂开发平台分析

• 概要
• 指示/阶段资产
• 依开发阶段划分的在研产品
• PDE9A 抑制剂的竞争格局
• 公司和阶段划分的管道产品
• PDE9A 抑制剂的临床和监管时间表

第4章 PDE9A抑制剂的收购，授权及联盟契约

• PDE9A 抑制剂收购、授权和交易价值
• PDE9A 抑制剂收购与授权（按交易类型和阶段划分的总价值）
• 正在开发中有前景的技术

第5章 PDE9A抑制剂开发平台(管线)的形势

• 简介概要
• 后期阶段的资产比较概要
• PDE9A抑制剂开发平台(管线)的药物简介
  • CRD-740(Cardurion Pharmaceuticals)
  • tobinontorin(Cardurion Pharmaceuticals)
  • irusenotorin(Eisai)
  • osoresunontorin(Boehringer Ingelheim)
  • PDE9A抑制剂(Ignota Labs)
  • 其他

第6章 PDE9A抑制剂的未来展望

第7章 SWOT分析

第8章 附录

The PDE9A inhibitor space is at an inflection point-backed by a growing market, significant unmet needs, and strong clinical rationale. Companies positioned with best-in-class selectivity, clinical differentiation, and strategic partnerships stand to capture a multi-billion-dollar opportunity in cardiovascular and cognitive therapeutics.

Phosphodiesterase 9A (PDE9A) has emerged as a high-value target in drug development, particularly for its role in cardiovascular and neurodegenerative diseases. By modulating cyclic nucleotide levels, PDE9A inhibitors offer a novel mechanism of action that could translate into groundbreaking therapies for heart failure (HFpEF, HFrEF), Alzheimer's disease, and schizophrenia. However, despite their promise, no PDE9A inhibitor has been approved for clinical use yet-leaving a high-risk, high-reward opportunity for drug developers and investors.

Mechanism of Action: A New Class of cGMP Modulators

PDE9A plays a pivotal role in intracellular signal transduction, regulating cGMP and cAMP levels. By blocking PDE9A activity, inhibitors prevent the degradation of these key signaling molecules, leading to enhanced vasodilation, neuroprotection, and metabolic regulation. This mechanism positions PDE9A inhibitors as a potential breakthrough in cardiovascular and neurological treatment paradigms, particularly for conditions where cGMP dysregulation is implicated.

Market Overview: Competitive and Expanding Landscape

The PDE9A inhibitors market is highly dynamic, with many active drug candidates in development by key players, including:

• Cardurion Pharmaceuticals - Leading the pipeline with two assets under development.
• Ignota Labs - Backed by $6.9M in seed funding, focusing on AI-driven drug discovery.
• Eisai & Boehringer Ingelheim - Exploring PDE9A inhibitors across heart failure and neurological indications.

Clinical progress is accelerating, with:

• 60% of PDE9A inhibitors in Phase II trials
• 20% in Phase I trials
• 20% in preclinical development

Despite this momentum, selectivity challenges remain-particularly in distinguishing PDE9A from other phosphodiesterases like PDE1, which, if inhibited, could lead to CNS-related side effects.

Commercial Opportunity: Market Growth & Investment Potential

The broader PDE inhibitors market is projected to grow from $4.06 billion in 2024 to $6.92 billion by 2032 at a CAGR of 6.88%. This surge is fueled by:

• The rising prevalence of heart failure (expected to cost the U.S. $70 billion annually by 2030).
• The Alzheimer's market reaching $1 trillion in costs by 2050, highlighting the urgent need for disease-modifying treatments.
• Increased biopharma investment in neurotherapeutics and cardiovascular innovations.

With no approved PDE9A inhibitors yet, early-stage investments could lead to first-mover advantages, especially in partnerships, acquisitions, and licensing deals.

Strategic Insights from Mellalta Meets' 2025 Report

The PDE9A Inhibitor - Pipeline Analytics 2025 Report by Mellalta Meets provides in-depth market intelligence, covering:

• Pipeline Breakdown - Companies, Products in various development phases.
• Clinical Trial Analysis - Key regions, interventions, and trial outcomes.
• Competitive Intelligence - Acquisition targets, licensing deals, and funding trends.
• Indication Prioritization - Identifying high-value opportunities in PDE9A drug development.

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

• 2.1. Introduction and Role of PDE9A inhibitors
• 2.2. Potential Concern with PDE9A Inhibitors
• 2.3. PDE9A Inhibitors: A Highly-Potential Target in Cardiovascular Space
• 2.4. Clinical Applications of PDE9A Inhibitors

3. PDE9A INHIBITOR PIPELINE ANALYSIS

• 3.1. Overview
• 3.2. Assets by Indication/Phase
• 3.3. Pipeline Products by Stage of Development
• 3.4. PDE9A Inhibitor Competitive Landscape
• 3.5. Pipeline Products by Company and Phases
• 3.6. PDE9A Inhibitor Clinical & Regulatory Timelines

4. PDE9A INHIBITOR ACQUISITIONS, LICENSING AND COLLABORATION DEALS

• 4.1. PDE9A Inhibitor Acquisitions, Licensing and Deal values
• 4.2. PDE9A Inhibitor Acquisitions, Licensing by Transaction type and total amount size by Phases
• 4.3. Promising Technologies Under development

5. PDE9A Inhibitor PIPELINE LANDSCAPE

• 5.1. Profile at Glance
• 5.2. Late-Stage Assets Comparisons At-a-glance
• 5.3. PDE9A Inhibitor Pipeline Drug Profiles
  • 5.3.1. CRD-740 (Cardurion Pharmaceuticals)
    • 5.3.1.1. Product Profile & Description
    • 5.3.1.2. Collaborations
    • 5.3.1.3. Other Developments
    • 5.3.1.4. Clinical Trials
  • 5.3.2. Tovinontrine (Cardurion Pharmaceuticals)
    • 5.3.2.1. Product Profile & Description
    • 5.3.2.2. Collaborations
    • 5.3.2.3. Other Developments
    • 5.3.2.4. Clinical Trials
  • 5.3.3. Irsenontrine (Eisai)
    • 5.3.3.1. Product Profile & Description
    • 5.3.3.2. Collaborations
    • 5.3.3.3. Other Developments
    • 5.3.3.4. Clinical Trials
  • 5.3.4. Osoresnontrine (Boehringer Ingelheim)
    • 5.3.4.1. Product Profile & Description
    • 5.3.4.2. Collaborations
    • 5.3.4.3. Other Developments
    • 5.3.4.4. Clinical Trials
  • 5.3.5. PDE9A inhibitor (Ignota Labs)
    • 5.3.5.1. Product Profile & Description
    • 5.3.5.2. Collaborations
    • 5.3.5.3. Other Developments
  • 5.3.6. Others...

6. PDE9A INHIBITOR FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX